High Containment Granulation High Containment with Maximum Safety for Minimal Volumes

Author / Editor: Anke Geipel-Kern* / Anke Geipel-Kern

How do you shrink an entire granulation line — including containment — to the size of a laboratory? — Glatt has come up with a cost-optimized containment solution with the help of barrier manufacturer Weiss Pharmatechnik. The system makes it possible to operate several laboratory processes in sequence using only one barrier system.

Related Vendors

Smoke studies show the airflow in the barrier system.
Smoke studies show the airflow in the barrier system.
(Pictures: Glatt)

Containment is a hot topic in pharmaceutical production at the moment. According to studies, one in every four ingredients is highly active and requires safety protection devices when being processed. However, before deciding to invest in a containment system, a pharma company first has to answer a few questions and get a few facts straight:

  • What are the toxicity characteristics of the API?
  • What is the concentration of the active ingredient?
  • What about frequency of exposure?
  • Does the company want to invest in PPE or in containment?

In other words: Does it need a large — and therefore more expensive — solution, or would a smaller option do?

Lab Costs Down

As far as its laboratories go, Glatt has introduced measures to cut expenses in the development of the new containment laboratory technology on the grounds that its defined goal is low investment costs. “Isolators are costly to build, and generally they are only one dedicated solution for one apparatus,” explains Michael Maintok, Head of Engineering Customized Solutions, Glatt.

The growing number of highly active ingredients and the resultant employee safety protection requirements could see costs exploding in the development laboratories too. Especially those involved in galenic development have to process very different active ingredients one after the other in a short space of time using the same equipment.